Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis

Abstract Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vincenza Conteduca, Sheng-Yu Ku, Luisa Fernandez, Angel Dago-Rodriquez, Jerry Lee, Adam Jendrisak, Megan Slade, Cole Gilbertson, Jyothi Manohar, Michael Sigouros, Yipeng Wang, Ryan Dittamore, Rick Wenstrup, Juan Miguel Mosquera, Joseph D. Schonhoft, Himisha Beltran
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/192f8c4983314673aa85a47274caaba0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:192f8c4983314673aa85a47274caaba0
record_format	dspace
spelling	oai:doaj.org-article:192f8c4983314673aa85a47274caaba02021-12-02T15:07:53ZCirculating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis10.1038/s41698-021-00211-12397-768Xhttps://doaj.org/article/192f8c4983314673aa85a47274caaba02021-08-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00211-1https://doaj.org/toc/2397-768XAbstract Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer.Vincenza ConteducaSheng-Yu KuLuisa FernandezAngel Dago-RodriquezJerry LeeAdam JendrisakMegan SladeCole GilbertsonJyothi ManoharMichael SigourosYipeng WangRyan DittamoreRick WenstrupJuan Miguel MosqueraJoseph D. SchonhoftHimisha BeltranNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Vincenza Conteduca Sheng-Yu Ku Luisa Fernandez Angel Dago-Rodriquez Jerry Lee Adam Jendrisak Megan Slade Cole Gilbertson Jyothi Manohar Michael Sigouros Yipeng Wang Ryan Dittamore Rick Wenstrup Juan Miguel Mosquera Joseph D. Schonhoft Himisha Beltran Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
description	Abstract Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer.
format	article
author	Vincenza Conteduca Sheng-Yu Ku Luisa Fernandez Angel Dago-Rodriquez Jerry Lee Adam Jendrisak Megan Slade Cole Gilbertson Jyothi Manohar Michael Sigouros Yipeng Wang Ryan Dittamore Rick Wenstrup Juan Miguel Mosquera Joseph D. Schonhoft Himisha Beltran
author_facet	Vincenza Conteduca Sheng-Yu Ku Luisa Fernandez Angel Dago-Rodriquez Jerry Lee Adam Jendrisak Megan Slade Cole Gilbertson Jyothi Manohar Michael Sigouros Yipeng Wang Ryan Dittamore Rick Wenstrup Juan Miguel Mosquera Joseph D. Schonhoft Himisha Beltran
author_sort	Vincenza Conteduca
title	Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
title_short	Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
title_full	Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
title_fullStr	Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
title_full_unstemmed	Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
title_sort	circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/192f8c4983314673aa85a47274caaba0
work_keys_str_mv	AT vincenzaconteduca circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT shengyuku circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT luisafernandez circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT angeldagorodriquez circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT jerrylee circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT adamjendrisak circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT meganslade circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT colegilbertson circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT jyothimanohar circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT michaelsigouros circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT yipengwang circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT ryandittamore circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT rickwenstrup circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT juanmiguelmosquera circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT josephdschonhoft circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis AT himishabeltran circulatingtumorcellheterogeneityinneuroendocrineprostatecancerbysinglecellcopynumberanalysis
_version_	1718388368738353152

Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis

Ejemplares similares